E Poster Session News Today

Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission

Investegate announcements from Galapagos NV, Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting Share Article Trial in progress poster: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors NEW YORK (PRWEB) June 03, 2021 Dracen Pharmaceuticals Inc., announced today that a poster presentation updating the ongoing Phase 1/2a, FIH study of DRP-104, a broad glu...

MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter- - MEI Maintains Strong Financial Position with ~$164 Million in Cash- News provided by Share this article Share this article SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cance...

MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter- - MEI Maintains Strong Financial Position with ~$164 Million in Cash- News provided by Share this article Share this article SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cance...

Share this article Share this article BOTHELL, Wash., April 13, 2021 /PRNewswire/ -- Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics), an emerging biotechnology company focused on developing a novel MabPair ™ platform for antibody-based combination therapies for the treatment of cancer, inflammation and autoimmune disease, announced a clinical update on its first MabPair product PSB205 at the American Association for Cancer Research (AACR) Annual Meeting. Dr Li Zhang of Sun Yat-Sen Uni...

MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021 Investor and Analyst Video Webcast Event on Tuesday, April 13, 2021 at 8:00 AM Eastern Time News provided by Share this article Share this article SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused...

Abstract Control Number:  3578 Session Type: E-Poster Session Session Title: Biological Therapeutic Agents Permanent Abstract Number: 959 Abstract Control Number:  3677 Session Type: E-Poster Session Session Title: Biological Therapeutic Agents Permanent Abstract Number: 964 About ST101 ST101 is a peptide inhibitor of C/EBPβ, which is a transcription factor overexpressed in many cancers that regulate cellular differentiation and promote tumor survival and proliferation. ST101 significan...

Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting Share Article Posters further expand on preclinical immuno-oncology mechanism of action and combination therapy with various checkpoint inhibitors and confirm DRP-104 single agent activity in KEAP1 and STK11 mutant lung tumors and head and neck squamous cell carcinoma New York, NY (PRWEB) April 05, 2021 Dracen Pharmaceuticals, Inc., announced to...

Search jobs 10-Mar-2021 LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today ...